I've never
"dropped" as we used to say in the sixties, but I have fellow farmer friends that have, they didn't look too ready to "bed down", but that was just an observation. The real observation for me is how do LSD and failed pot Co's like say FSD or "HUGE" work their way onto the "NAS" with, well..."at the end of the day", quite "frankly" nothing?
Note that MMED or mindmedicine, the company below, ready to LSD peeps up and study their sleep patterns is worth about 20 TIMES that of
"fist full of FDA approvals" and "effortless revenue co" EDT....IS it intentional... does doing 230K CAD with 183K of it an aknewity from a major US pharma buy design? better do your homework...the fact that planted posters need to "shower" in between each "
purposeful, planted, per protocol post" is likely just the price of selling your soul to the $DEVIL$ ...just my humble opinion...do read up on the LSD co valued at 20 times that of EDT it is enlightening indeed.
Mind Medicine begins recruitment for LSD sleep study
2021-11-16 11:40 ET - News Release
Dr. Miri Wernli reports
MINDMED LAUNCHES STUDY OF LOW-DOSE LSD EFFECTS ON SLEEP AND COGNITIVE MEASURES
Mind Medicine (MindMed) Inc. has launched recruitment for a randomized placebo-controlled study evaluating the effects of daytime and evening administration of repeated low doses of LSD.
Researchers will use digital measurement devices and software to measure the effects of microdoses of LSD on neuroplasticity markers such as BDNF plasma levels as well as on various sleep measures, mood, cognitive performance, regulation of emotions, quality of life and immune system response. The study will be conducted by Dr. Kim Kuypers of Maastricht University, a leading global authority on the use of low-dose psychedelics.
"Research into the practice of taking repeated low doses of psychedelics starts with the basics, looking at whether there is a time of day that influences the impact of these treatments," said Dr. Kuypers. "We are investigating whether the repeated intake of lower doses could lead to realignment of patterns of thinking that would enable individuals to access levels of self-awareness that can provide an enriched experience of life."
"Increasingly, claims are being made about so-called microdosing of psychedelics regarding the potential to impact mental and physical well-being, cognition, memory, and specific aspects such as creativity and productivity," said Dr. Miri Halperin Wernli, MindMed's executive president. "However, scientific evidence to support or even fully explore the safety and benefits claimed has been lacking. With our innovative study design, integrating digital medicine measurement techniques with more traditional self-reporting and cognitive tasks, our goal is to provide insight on key parameters that may impact and explain the mechanisms behind low-dose treatments. These parameters include diurnal versus nocturnal differences and possible cumulative effects due to repeated administration. This regimen could provide new tools to deal with various pathologies, helping to unblock pathological ways of thinking by shifting an individual's perspective, catalyzing insights, and ultimately changing problematic and habitual mindsets and behaviours."
About Mind Medicine (MindMed) Inc.
MindMed is a clinical-stage psychedelic medicine biotech company that seeks to discover, develop and deploy psychedelic-inspired medicines and therapies to address addiction and mental illness. The company is assembling a compelling drug development pipeline of innovative treatments based on psychedelic substances including psilocybin, LSD, MDMA, DMT and an ibogaine derivative, 18-MC. The MindMed executive team brings extensive biopharmaceutical experience to MindMed's approach to developing the next generation of psychedelic-inspired medicines and therapies.
MindMed trades on the Nasdaq Stock Market under the symbol MNMD and on the NEO Exchange under the symbol MMED. MindMed is also traded in Germany under the symbol MMQ.
We seek Safe Harbor.
© 2021 Canjex Publishing Ltd. All rights reserved.